Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patientsAlejandro Contreras, MF Rimawi, Jae C. Chang et al.|Cancer Research|2013Cited by 18